4.6 Article

Impact of malignancy on clinical outcomes in patients with acute coronary syndromes

Journal

INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 328, Issue -, Pages 8-13

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2020.12.010

Keywords

Acute coronary syndrome; Cancer; Malignancy; Outcomes

Funding

  1. Swiss National Research Foundation (Special Programme University Medicine) [SPUM 33CM30-124112, 32473B_163271, 310030_165990]
  2. AstraZeneca (Zug Switzerland)
  3. Roche Diagnostics (Rotkreuz, Switzerland)
  4. Medtronic (Tolochenaz, Switzerland)
  5. Foundation for Cardiovascular Research - Zurich Heart House, Zurich
  6. H.H. Shaikh Khalifa Bin Hamad Al-Thani Heart Research Programme
  7. Eli Lilly, (Indianapolis, USA)
  8. Merck Sharpe and Dome (MSD, Lucerne, Switzerland)
  9. Swiss National Science Foundation (SNF) [310030_165990] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

This study investigated the prevalence and prognostic influence of cancer in patients with acute coronary syndrome, finding that patients with cancer, especially those with solid tumors, had a higher rate of major cardiovascular events and mortality at one-year follow-up compared to non-cancer patients. Cancer was identified as an independent risk factor for poor outcomes in ACS patients.
Background: The impact of cancer on survival in patients with coronary artery disease has not been well defined. We designed the present study to explore the prevalence and prognostic influence of cancer in patients with acute coronary syndrome (ACS). Methods: 2132 patients with ACS were enrolled in the prospective, multicenter Special Program University Medicine ACS (SPUM-ACS) cohort. The primary endpoints of major cardiovascular and cerebrovascular events (MACCE) and death were independently adjudicated at 30-day and at one-year follow-up. Results: Of the 2 ' 132 ACS patients 7.74% (n = 165) had cancer. At 30-day, except for net adverse clinical events (NACE defined as MACCE plus major bleeding), outcomes did not differ significantly between the two groups. At one year, MACCE rate was higher in cancer than in non-cancer patients (21.8 vs. 12.2%, p < 0.001). Even after adjusting for covariates, one-year all-cause mortality was higher in cancer patients than in those without (30.3% vs. 11.9%; p < 0.0001) as was cardiovascular mortality (15.7% vs. 5.9%; p < 0.001) and revascularization (12.7% vs. 5.5%, p < 0.001). Net adverse clinical events were also higher in patients with cancer at one-year follow-up (33.9% vs. 19.8%, p < 0.001). A sub-analysis revealed that those with solid tumors, but not hematological malignancies were more likely to experience MACCE (p = 0.001) as well as a higher cardiovascular and all cause mortality (both p = 0.001) at one-year follow-up. Conclusions: ACS patients with cancer, specifically those with solid tumors, have a higher MACCE as well as cardiovascular and total mortality rate than non-cancer patients independent of cardiovascular risk factors. Thus, cancer is an independent risk factor for a poor outcome in ACS patients. Crown Copyright <(c)> 2020 Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available